At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MAZE Maze Therapeutics
Post-Mkt 08-26 19:28:22 EDT
29.58
-0.84
-2.76%
盘后29.58
+0.000.00%
16:20 EDT
High30.40Low29.33Vol230.08K
Open30.26D1 Closing30.42Amplitude3.52%
Mkt Cap1.63BTradable Cap1.10BTotal Shares55.25M
T/O6.83MT/O Rate0.62%Tradable Shares37.25M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Maze Therapeutics Director Paula A. Johnson Files Initial Beneficial Ownership Statement
Reuters  ·  08-18
Maze Therapeutics Director Paula A. Johnson Files Initial Beneficial Ownership Statement
Maze Therapeutics Names Paula Johnson, Sophie Kornowski to Board of Directors
Reuters  ·  08-18
Maze Therapeutics Names Paula Johnson, Sophie Kornowski to Board of Directors
Maze Therapeutics President, R&D and CMO Harold Bernstein Disposes of USD 445,522 Common Shares
Reuters  ·  08-15
Maze Therapeutics President, R&D and CMO Harold Bernstein Disposes of USD 445,522 Common Shares
Maze Therapeutics Adds Paula Johnson, Sophie Kornowski to Board
Reuters  ·  08-14
Maze Therapeutics Adds Paula Johnson, Sophie Kornowski to Board
Maze Therapeutics Announces Appointments to Its Board of Directors
THOMSON REUTERS  ·  08-14
Maze Therapeutics Announces Appointments to Its Board of Directors
CAMP4 Therapeutics Q2 Loss Per Share Misses Estimates on Non-Cash Derivative Charge
Reuters  ·  08-14
CAMP4 Therapeutics Q2 Loss Per Share Misses Estimates on Non-Cash Derivative Charge
Legal and Regulatory Risks Threaten Maze Therapeutics’ Funding, Reputation and Path to Commercialization
TIPRANKS  ·  08-13
Legal and Regulatory Risks Threaten Maze Therapeutics’ Funding, Reputation and Path to Commercialization
Belite Bio Q2 Net Loss Widens on Higher Expenses
Reuters  ·  08-13
Belite Bio Q2 Net Loss Widens on Higher Expenses
Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Maze Therapeutics, Inc. (MAZE) and Immunome (IMNM)
TIPRANKS  ·  08-12
Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Maze Therapeutics, Inc. (MAZE) and Immunome (IMNM)
Humacyte Q2 Net Loss Widens on Inventory, Production Costs
Reuters  ·  08-12
Humacyte Q2 Net Loss Widens on Inventory, Production Costs
Switzerland's Pharvaris Q2 Loss Narrows, Cash Rises to €318 Mln
Reuters  ·  08-12
Switzerland's Pharvaris Q2 Loss Narrows, Cash Rises to €318 Mln
Maze Therapeutics: Buy Rating Reaffirmed as Clinical De-Risking Supports Unchanged $110 Price Target
TIPRANKS  ·  08-12
Maze Therapeutics: Buy Rating Reaffirmed as Clinical De-Risking Supports Unchanged $110 Price Target
Maze Therapeutics Price Target Maintained with a $46.00/Share by BTIG
Dow Jones  ·  08-12
Maze Therapeutics Price Target Maintained with a $46.00/Share by BTIG
Press Release: MindMaze Therapeutics Appoints Prof. John W. Krakauer as Strategic Advisor
Dow Jones  ·  08-12
Press Release: MindMaze Therapeutics Appoints Prof. John W. Krakauer as Strategic Advisor
Maze Therapeutics Q2 EPS $(0.76) Misses $(0.73) Estimate
Benzinga Earnings  ·  08-12
Maze Therapeutics Q2 EPS $(0.76) Misses $(0.73) Estimate
Earnings Flash (MAZE) Maze Therapeutics Posts Q2 Loss $0.76 per Share, vs. FactSet Est of $0.72 Loss
MT Newswires Live  ·  08-12
Earnings Flash (MAZE) Maze Therapeutics Posts Q2 Loss $0.76 per Share, vs. FactSet Est of $0.72 Loss
Maze Therapeutics reports Q2 EPS (76c), consensus (70c)
TIPRANKS  ·  08-12
Maze Therapeutics reports Q2 EPS (76c), consensus (70c)
Maze Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-12
Maze Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary
Maze Therapeutics Rugi Bersih Q2 FY26 Melebar Ke USD 44,7 Juta; Rugi Per Saham Naik Ke USD 0,76
Reuters  ·  08-12
Maze Therapeutics Rugi Bersih Q2 FY26 Melebar Ke USD 44,7 Juta; Rugi Per Saham Naik Ke USD 0,76
Maze Therapeutics Inc Q2 Income from Operations USD -48.035 Million VS. Ibes Estimate USD -45.2 Million
THOMSON REUTERS  ·  08-12
Maze Therapeutics Inc Q2 Income from Operations USD -48.035 Million VS. Ibes Estimate USD -45.2 Million

Introduction

Company Name.
Maze Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Issue price:
--